Apollo Endosurgery announces results from Orbera study at Digestive Disease Week.
Apollo Endosurgery announced the presentation of results from Mayo Clinic's prospective open-label study of the Orbera Intragastric Balloon in patients with Nonalcoholic Steatohepatitis, or NASH, at Digestive Disease Week 2018. The FDA-approved study demonstrated the significant benefits of weight loss with the Orbera Intragastric Balloon in patients with NASH and nonalcoholic fatty liver disease. Liver scarring is a feared complication that constitutes the driving force behind the development of the cirrhosis syndrome, which can only be adequately treated by liver transplantation when the organ decompensates. These benefits were also coupled with significant weight loss and improvements in other key risk factors for cardiovascular disease and diabetes. On average, patients achieved total body weight loss of 12% in the 6 months with their Orbera balloon. Eighty percent of patients were able to achieve the minimum recommended weight loss of 7% total body weight loss. Additionally, there were notable and statistically significant improvements in key metabolic factors such as diabetes related HbA1c and waist circumference.
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 5, 2018|
|Previous Article:||Lionsgate announces multi-year licensing agreement with Stan in Australia.|
|Next Article:||Piper views FDA update as positive news for Apollo Endosurgery.|